Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival

Pamela Samson, Varun Puri, A. Craig Lockhart, Clifford Robinson, Stephen Broderick, G. Alexander Patterson, Bryan Meyers, Traves Crabtree

Research output: Contribution to journalArticle

Abstract

Objectives: The study objectives were to identify variables associated with the use of adjuvant chemotherapy among patients with node-positive esophageal cancer who received induction therapy and to evaluate its relationship with overall survival. Methods: Treatment data for patients with esophageal cancer receiving induction chemotherapy ± radiotherapy and esophagectomy were abstracted from the National Cancer Data Base. Pathologic node-positive patients were dichotomized by whether they received 2 or more cycles of adjuvant chemotherapy or none. Kaplan–Meier survival curves were generated, and a Cox proportional hazards model was done to identify factors associated with overall survival. Results: From 2006 to 2012, 3100 patients had pathologic positive nodes after induction therapy and esophagectomy. A total of 2625 patients (84.7%) did not receive adjuvant chemotherapy, and 475 patients (15.3%) did. N3 nodal stage was associated with an increased likelihood of receiving adjuvant chemotherapy (reference: N1, odds ratio, 1.82, 95% confidence interval, 1.15-2.97, P =.01), whereas increasing age (by year, odds ratio, 0.97, confidence interval, 0.96-0.98, P <.001), induction chemoradiation therapy (reference: induction chemotherapy, odds ratio, 0.39, confidence interval, 0.30-0.52, P <.001), and increasing inpatient length of stay after esophagectomy (per day: odds ratio, 0.98, confidence interval, 0.97-0.99, P =.007) were associated with a decreased likelihood. Patients receiving adjuvant chemotherapy had improved overall survival at each pathologic nodal stage: 31.6 months versus 22.7 months for N1 disease (P <.001), 32.4 months versus 19.2 months for N2 disease (P =.035), and 19.5 months versus 10.4 months for N3 disease (P <.001). Adjuvant therapy was independently associated with decreased mortality hazard (hazard ratio, 0.69, 95% confidence interval, 0.57-0.83, P <.001). Conclusions: Patients receiving adjuvant chemotherapy after induction therapy and esophagectomy show a survival benefit at all positive nodal stages. Prospective studies may help further delineate this benefit.

Original languageEnglish (US)
JournalJournal of Thoracic and Cardiovascular Surgery
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Induction Chemotherapy
Adjuvant Chemotherapy
Esophageal Neoplasms
Esophagectomy
Survival
Confidence Intervals
Odds Ratio
Therapeutics
Proportional Hazards Models
Inpatients
Length of Stay
Radiotherapy
Databases
Prospective Studies
Mortality

Keywords

  • chemotherapy
  • esophageal cancer
  • esophagectomy
  • lymph nodes

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival. / Samson, Pamela; Puri, Varun; Lockhart, A. Craig; Robinson, Clifford; Broderick, Stephen; Patterson, G. Alexander; Meyers, Bryan; Crabtree, Traves.

In: Journal of Thoracic and Cardiovascular Surgery, 01.01.2018.

Research output: Contribution to journalArticle

Samson, Pamela ; Puri, Varun ; Lockhart, A. Craig ; Robinson, Clifford ; Broderick, Stephen ; Patterson, G. Alexander ; Meyers, Bryan ; Crabtree, Traves. / Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival. In: Journal of Thoracic and Cardiovascular Surgery. 2018.
@article{451613fbf19246e6aa5b1a18f285994d,
title = "Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival",
abstract = "Objectives: The study objectives were to identify variables associated with the use of adjuvant chemotherapy among patients with node-positive esophageal cancer who received induction therapy and to evaluate its relationship with overall survival. Methods: Treatment data for patients with esophageal cancer receiving induction chemotherapy ± radiotherapy and esophagectomy were abstracted from the National Cancer Data Base. Pathologic node-positive patients were dichotomized by whether they received 2 or more cycles of adjuvant chemotherapy or none. Kaplan–Meier survival curves were generated, and a Cox proportional hazards model was done to identify factors associated with overall survival. Results: From 2006 to 2012, 3100 patients had pathologic positive nodes after induction therapy and esophagectomy. A total of 2625 patients (84.7{\%}) did not receive adjuvant chemotherapy, and 475 patients (15.3{\%}) did. N3 nodal stage was associated with an increased likelihood of receiving adjuvant chemotherapy (reference: N1, odds ratio, 1.82, 95{\%} confidence interval, 1.15-2.97, P =.01), whereas increasing age (by year, odds ratio, 0.97, confidence interval, 0.96-0.98, P <.001), induction chemoradiation therapy (reference: induction chemotherapy, odds ratio, 0.39, confidence interval, 0.30-0.52, P <.001), and increasing inpatient length of stay after esophagectomy (per day: odds ratio, 0.98, confidence interval, 0.97-0.99, P =.007) were associated with a decreased likelihood. Patients receiving adjuvant chemotherapy had improved overall survival at each pathologic nodal stage: 31.6 months versus 22.7 months for N1 disease (P <.001), 32.4 months versus 19.2 months for N2 disease (P =.035), and 19.5 months versus 10.4 months for N3 disease (P <.001). Adjuvant therapy was independently associated with decreased mortality hazard (hazard ratio, 0.69, 95{\%} confidence interval, 0.57-0.83, P <.001). Conclusions: Patients receiving adjuvant chemotherapy after induction therapy and esophagectomy show a survival benefit at all positive nodal stages. Prospective studies may help further delineate this benefit.",
keywords = "chemotherapy, esophageal cancer, esophagectomy, lymph nodes",
author = "Pamela Samson and Varun Puri and Lockhart, {A. Craig} and Clifford Robinson and Stephen Broderick and Patterson, {G. Alexander} and Bryan Meyers and Traves Crabtree",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jtcvs.2018.05.100",
language = "English (US)",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival

AU - Samson, Pamela

AU - Puri, Varun

AU - Lockhart, A. Craig

AU - Robinson, Clifford

AU - Broderick, Stephen

AU - Patterson, G. Alexander

AU - Meyers, Bryan

AU - Crabtree, Traves

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: The study objectives were to identify variables associated with the use of adjuvant chemotherapy among patients with node-positive esophageal cancer who received induction therapy and to evaluate its relationship with overall survival. Methods: Treatment data for patients with esophageal cancer receiving induction chemotherapy ± radiotherapy and esophagectomy were abstracted from the National Cancer Data Base. Pathologic node-positive patients were dichotomized by whether they received 2 or more cycles of adjuvant chemotherapy or none. Kaplan–Meier survival curves were generated, and a Cox proportional hazards model was done to identify factors associated with overall survival. Results: From 2006 to 2012, 3100 patients had pathologic positive nodes after induction therapy and esophagectomy. A total of 2625 patients (84.7%) did not receive adjuvant chemotherapy, and 475 patients (15.3%) did. N3 nodal stage was associated with an increased likelihood of receiving adjuvant chemotherapy (reference: N1, odds ratio, 1.82, 95% confidence interval, 1.15-2.97, P =.01), whereas increasing age (by year, odds ratio, 0.97, confidence interval, 0.96-0.98, P <.001), induction chemoradiation therapy (reference: induction chemotherapy, odds ratio, 0.39, confidence interval, 0.30-0.52, P <.001), and increasing inpatient length of stay after esophagectomy (per day: odds ratio, 0.98, confidence interval, 0.97-0.99, P =.007) were associated with a decreased likelihood. Patients receiving adjuvant chemotherapy had improved overall survival at each pathologic nodal stage: 31.6 months versus 22.7 months for N1 disease (P <.001), 32.4 months versus 19.2 months for N2 disease (P =.035), and 19.5 months versus 10.4 months for N3 disease (P <.001). Adjuvant therapy was independently associated with decreased mortality hazard (hazard ratio, 0.69, 95% confidence interval, 0.57-0.83, P <.001). Conclusions: Patients receiving adjuvant chemotherapy after induction therapy and esophagectomy show a survival benefit at all positive nodal stages. Prospective studies may help further delineate this benefit.

AB - Objectives: The study objectives were to identify variables associated with the use of adjuvant chemotherapy among patients with node-positive esophageal cancer who received induction therapy and to evaluate its relationship with overall survival. Methods: Treatment data for patients with esophageal cancer receiving induction chemotherapy ± radiotherapy and esophagectomy were abstracted from the National Cancer Data Base. Pathologic node-positive patients were dichotomized by whether they received 2 or more cycles of adjuvant chemotherapy or none. Kaplan–Meier survival curves were generated, and a Cox proportional hazards model was done to identify factors associated with overall survival. Results: From 2006 to 2012, 3100 patients had pathologic positive nodes after induction therapy and esophagectomy. A total of 2625 patients (84.7%) did not receive adjuvant chemotherapy, and 475 patients (15.3%) did. N3 nodal stage was associated with an increased likelihood of receiving adjuvant chemotherapy (reference: N1, odds ratio, 1.82, 95% confidence interval, 1.15-2.97, P =.01), whereas increasing age (by year, odds ratio, 0.97, confidence interval, 0.96-0.98, P <.001), induction chemoradiation therapy (reference: induction chemotherapy, odds ratio, 0.39, confidence interval, 0.30-0.52, P <.001), and increasing inpatient length of stay after esophagectomy (per day: odds ratio, 0.98, confidence interval, 0.97-0.99, P =.007) were associated with a decreased likelihood. Patients receiving adjuvant chemotherapy had improved overall survival at each pathologic nodal stage: 31.6 months versus 22.7 months for N1 disease (P <.001), 32.4 months versus 19.2 months for N2 disease (P =.035), and 19.5 months versus 10.4 months for N3 disease (P <.001). Adjuvant therapy was independently associated with decreased mortality hazard (hazard ratio, 0.69, 95% confidence interval, 0.57-0.83, P <.001). Conclusions: Patients receiving adjuvant chemotherapy after induction therapy and esophagectomy show a survival benefit at all positive nodal stages. Prospective studies may help further delineate this benefit.

KW - chemotherapy

KW - esophageal cancer

KW - esophagectomy

KW - lymph nodes

UR - http://www.scopus.com/inward/record.url?scp=85050304894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050304894&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2018.05.100

DO - 10.1016/j.jtcvs.2018.05.100

M3 - Article

C2 - 30054137

AN - SCOPUS:85050304894

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

ER -